Cullinan Oncology Llc Stock Price Prediction
| CGEM Stock | USD 12.54 0.32 2.62% |
Oversold Vs Overbought
56
Oversold | Overbought |
EPS Estimate Next Quarter (0.83) | EPS Estimate Current Year (3.01) | EPS Estimate Next Year (3.13) | Wall Street Target Price 33 | EPS Estimate Current Quarter (0.81) |
Using Cullinan Oncology hype-based prediction, you can estimate the value of Cullinan Oncology LLC from the perspective of Cullinan Oncology response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Cullinan Oncology to buy its stock at a price that has no basis in reality. In that case, they are not buying Cullinan because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Cullinan Oncology after-hype prediction price | USD 13.18 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Cullinan |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cullinan Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cullinan Oncology After-Hype Price Prediction Density Analysis
As far as predicting the price of Cullinan Oncology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cullinan Oncology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cullinan Oncology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cullinan Oncology Estimiated After-Hype Price Volatility
In the context of predicting Cullinan Oncology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cullinan Oncology's historical news coverage. Cullinan Oncology's after-hype downside and upside margins for the prediction period are 9.53 and 16.83, respectively. We have considered Cullinan Oncology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cullinan Oncology is not too volatile at this time. Analysis and calculation of next after-hype price of Cullinan Oncology LLC is based on 3 months time horizon.
Cullinan Oncology Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Cullinan Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cullinan Oncology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cullinan Oncology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.57 | 3.65 | 0.71 | 0.02 | 10 Events / Month | 5 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
12.54 | 13.18 | 5.10 |
|
Cullinan Oncology Hype Timeline
Cullinan Oncology LLC is currently traded for 12.54. The entity has historical hype elasticity of 0.71, and average elasticity to hype of competition of -0.02. Cullinan is forecasted to increase in value after the next headline, with the price projected to jump to 13.18 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 5.1%, whereas the daily expected return is currently at -0.57%. The volatility of related hype on Cullinan Oncology is about 9125.0%, with the expected price after the next announcement by competition of 12.52. Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Cullinan Oncology Basic Forecasting Models to cross-verify your projections.Cullinan Oncology Related Hype Analysis
Having access to credible news sources related to Cullinan Oncology's direct competition is more important than ever and may enhance your ability to predict Cullinan Oncology's future price movements. Getting to know how Cullinan Oncology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cullinan Oncology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.20) | 6.21 | (9.35) | 34.87 | |
| HCWB | HCW Biologics | 0.01 | 5 per month | 7.39 | 0.1 | 22.00 | (13.64) | 352.85 | |
| SCPH | Scpharmaceuticals | (0.30) | 7 per month | 0.00 | (0.20) | 4.30 | (7.09) | 20.70 | |
| MIST | Milestone Pharmaceuticals | (0.01) | 6 per month | 1.60 | 0.1 | 7.19 | (2.11) | 18.66 | |
| MCRB | Seres Therapeutics | (0.06) | 9 per month | 5.68 | (0.02) | 10.00 | (9.78) | 28.84 | |
| LUMO | Lumos Pharma | (0.13) | 6 per month | 2.60 | 0.11 | 6.35 | (5.19) | 26.13 |
Cullinan Oncology Additional Predictive Modules
Most predictive techniques to examine Cullinan price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cullinan using various technical indicators. When you analyze Cullinan charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Cullinan Oncology Predictive Indicators
The successful prediction of Cullinan Oncology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cullinan Oncology LLC, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cullinan Oncology based on analysis of Cullinan Oncology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Cullinan Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cullinan Oncology's related companies. | 2010 | 2023 | 2024 (projected) | Interest Debt Per Share | 0.003941 | 0.0347 | 0.0364 | Revenue Per Share | 0.43 | 0.38 | 0.34 |
Story Coverage note for Cullinan Oncology
The number of cover stories for Cullinan Oncology depends on current market conditions and Cullinan Oncology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cullinan Oncology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cullinan Oncology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Cullinan Oncology Short Properties
Cullinan Oncology's future price predictability will typically decrease when Cullinan Oncology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cullinan Oncology LLC often depends not only on the future outlook of the potential Cullinan Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cullinan Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.5 M | |
| Cash And Short Term Investments | 467.1 M |
Check out Cullinan Oncology Basic Forecasting Models to cross-verify your projections. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.